Head-to-head · WeighScore
Belle Health vs Sprout Health
The verdict
Sprout Health takes it — 86.4/100 to 77/100.
Sprout Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A LegitScript-certified desk that pairs low-cost compounded semaglutide and tirzepatide with a real brand-name Wegovy and Zepbound path — and a near-frictionless, often visit-free start.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Belle Health | Sprout Health |
|---|---|---|
| WeighScore | 77/100 | 86.4/100 |
| Grade | C+ | B |
| Scorecard rank | #48 | #6 |
| Semaglutide | $119/mo | $149/mo |
| Tirzepatide | $199/mo (all doses, 3-month plan, compounded) | $199/mo |
| Coverage | All 50 states | Not disclosed |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #48 · C+
Strengths
- Five named compounding pharmacy partners disclosed (Striker, Strive, OptioRx, Enovex, Braun PharmaCare)
- Flat-rate pricing — $119/mo semaglutide, $199/mo tirzepatide — doesn't rise at higher doses
- Free weekly registered-dietitian sessions included
- Operating since 2017
- LegitScript Certified
Where it loses points
- $199 tirzepatide price requires a 3-month bundle commitment
- Compounded medications are not FDA-approved
- Multi-pharmacy model — formulations may differ across orders
- FDA issued this company a warning letter dated 20 February 2026; the letter is public in FDA's warning-letter database
Graded #6 · B
Strengths
- LegitScript-certified with a listed address and contact line
- Both compounded ($149 semaglutide / $199 tirzepatide) and a genuine brand-name Wegovy/Zepbound route
- Low-friction intake — no labs and often no telehealth visit required
Where it loses points
- Compounded semaglutide and tirzepatide are not FDA-approved
- No oral or sublingual route — injectable only
- Thin transparency — no named medical director, and state availability is quiz-gated
- "No labs, no visit" convenience also means lighter clinical oversight
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.